Esperion Therapeutics Inc (NASDAQ: ESPR) reported encouraging top line results from its Phase 2 -035 and Phase 1 -037 trials, which Credit Suisse’s Vamil Divan believes addresses questions regarding the safety of combined bempedoic acid with high dose statins.
Divan maintained an Underperform rating on the company, while raising the price target from $10 to $14.
“Our POS for bempedoic acid making it to the market is now 75 percent and we also believe there is a 75 percent chance that the FDA will allow them to make it to the market prior to the completion of the CLEAR Outcomes trial,” the analyst mentioned.
However, Divan also pointed to outstanding questions regarding the competitive and regulatory landscape that Esperion would need to navigate.
For -035, the study results do reveal drug-related adverse effects, such as muscle cramps and intermittent myalgias, although the overall safety profile was “very reassuring.”
The results also reveal a 22 percent decrease in LDL-C levels, as compared to the placebo group, with 35 percent reduction in hsCRP levels.
“From a PK perspective, a 22 percent increase in the area under the curve in -035 is also reassuring and helps alleviate some of the concerns that we previously had,” Divan stated.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email email@example.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Latest Ratings for ESPR
View More Analyst Ratings for ESPR
View the Latest Analyst Ratings
See more from Benzinga
- JPMorgan Solid Q3 Driven By FICC Revenue
- Progressive Upgraded Following Lowered Estimates
- Bluebird's Gene Therapy Is Firing On All Cylinders
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.